ERBB2 and breast cancer: Overall, challenge of encapsulated 3D co-cultures of HER2+ BC aggregates and PBMCs with trastuzumab and pertuzumab led to an expressive reduction of the potentially immunosuppressive PD-L1+ myeloid cell population, in particular in the CD14+ monocytic population.